SironRX Therapeutics Inc. is betting that a product encoding a protein naturally produced by the body in response to tissue injury, and known to recruit stem cells, can become a drug effective at healing wounds and preventing skin scarring. The start-up got rights to Stromal cell-Derived Factor-1 from Juventas Therapeutics and Cleveland Clinic.
10000 Cedar Avenue
Cleveland, OH 44106
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
